Indications and uses
temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily relieves sinus congestion and pressure shrinks swollen nasal membranes so you can breathe more freely
temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily relieves sinus congestion and pressure shrinks swollen nasal membranes so you can breathe more freely
adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period. children under 6 years of age: ask a doctor. To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
store between 20° to 25°C (68° to 77°F) retain carton for future reference on full labeling
Drug Facts
Oxymetazoline hydrochloride 0.05%
Nasal decongestant
Stop use and ask a doctor if symptoms persist
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
benzalkonium chloride solution, benzyl alcohol, camphor, edetate disodium, eucalyptol, menthol, polysorbate 80, propylene glycol, purified water, sodium phosphate dibasic, sodium phosphate monobasic
Questions or comments? 1-800-317-2165
Afrin®
Oxymetazoline HCl Nasal Solution-Nasal Decongestant
Severe Congestion
NASAL SPRAY
Fast, Powerful
Congestion
Relief
Colds • Allergies
up to 12
Hour
Relief
Maximum
Strength
plus Menthol
#1 Doctor & Pharmacist
Recommended Nasal Brand
BAYER
1/2 FL OZ (15 mL)
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1000992 | Afrin 0.05 % Nasal Spray | PSN | 9 |
| 1000990 | oxymetazoline HCl 0.05 % Nasal Spray | PSN | 9 |
| 1000992 | oxymetazoline hydrochloride 0.5 MG/ML Nasal Spray [Afrin] | SBD | 9 |
| 1000990 | oxymetazoline hydrochloride 0.5 MG/ML Nasal Spray | SCD | 9 |
| 1000992 | Afrin 0.05 % Nasal Spray | SY | 9 |
| 1000992 | Afrin 0.5 MG/ML Nasal Spray | SY | 9 |
| 1000990 | oxymetazoline hydrochloride 0.05 % Nasal Spray | SY | 9 |
| Class | Version | Type | Effective |
|---|---|---|---|
| OXYMETAZOLINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| e67be450-f8e4-4bc1-88bd-1259d379f55f | Product name | 1 | 20210127 |
| c53f3286-4062-4cf5-8355-399519c639a6 | Product name | 1 | 20170424 |
| a993dfc5-f219-4460-bde6-30dd724d9ef0 | Product name | 1 | 20160818 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 11523-7020-1 | AfrinSevere Congestion | 1 in 1 CARTON | SPRAY | 1 | 9 | |
| 11523-7020-1 | AfrinSevere Congestion | 15 mL in 1 BOTTLE, SPRAY | SPRAY | 15 | 9 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 11523-7020-1 | ML - Milliliter | 11523-7020 | fc3de170-d4de-45f4-a4cf-0d8f24558ee0 | 1 | 2013-09-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Oxymetazoline hydrochloride | ACTIVE INGREDIENT | K89MJ0S5VY | 1 | |
| Oxymetazoline | ACTIVE MOIETY | 8VLN5B44ZY | 1 | |
| benzalkonium chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| benzyl alcohol | INACTIVE INGREDIENT | LKG8494WBH | 1 | |
| camphor (synthetic) | INACTIVE INGREDIENT | 5TJD82A1ET | 1 | |
| edetate disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| eucalyptol | INACTIVE INGREDIENT | RV6J6604TK | 1 | |
| menthol | INACTIVE INGREDIENT | L7T10EIP3A | 1 | |
| polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 1 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| sodium phosphate, dibasic | INACTIVE INGREDIENT | GR686LBA74 | 1 | |
| sodium phosphate, monobasic | INACTIVE INGREDIENT | 3980JIH2SW | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 11523-7020 | 11523-7020-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| BENZYL ALCOHOL | LKG8494WBH | IACT |
| CAMPHOR (SYNTHETIC) | 5TJD82A1ET | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| EUCALYPTOL | RV6J6604TK | IACT |
| MENTHOL | L7T10EIP3A | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | IACT |
| SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | IACT |
| OXYMETAZOLINE HYDROCHLORIDE | K89MJ0S5VY | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| eucalyptol | EUCALYPTOL | RV6J6604TK | JELLY / NASAL | 68.5 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | CONCENTRATE / ORAL | 17 mg/5ml | ||
| menthol | MENTHOL | L7T10EIP3A | JELLY / NASAL | 32.5 mg | ||
| menthol | MENTHOL | L7T10EIP3A | INHALANT / NASAL | 32 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SPRAY / NASAL | 0.01 mg | ||
| menthol | MENTHOL | L7T10EIP3A | DROPS / NASAL | 40.32 mg | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | SPRAY / NASAL | 5 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | FILM, SOLUBLE / ORAL | 9 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SOLUTION / ORAL | 25 mg/5ml | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION / INTRAVENOUS | 161 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SOLUTION / ORAL | 40 mg/1ml | ||
| eucalyptol | EUCALYPTOL | RV6J6604TK | DROPS / NASAL | 0.2 mg/1ml | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| eucalyptol | EUCALYPTOL | RV6J6604TK | SOLUTION / NASAL | 0.2 mg/1ml | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | CONCENTRATE / ORAL | 17 mg/5ml | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | TABLET, EXTENDED RELEASE / ORAL | 143 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SYRUP / ORAL | 70 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRADERMAL | 0.2 %w/v | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / IONTOPHORESIS | 14.2 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | CREAM / TOPICAL | 0.1 %w/w | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | TABLET / ORAL | 2 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAMUSCULAR | 40 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION / INTRAMUSCULAR | 161 mg | ||
| menthol | MENTHOL | L7T10EIP3A | INHALANT / NASAL | 32 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | CREAM / TOPICAL | 0.1 %w/w | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / TOPICAL | 14.2 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SUSPENSION / OPHTHALMIC | 0.43 %w/w | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 0.22 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / SUBCUTANEOUS | 14 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRADERMAL | 0.2 %w/v | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | TABLET, EXTENDED RELEASE / ORAL | 143 mg | ||
| camphor (synthetic) | CAMPHOR (SYNTHETIC) | 5TJD82A1ET | JELLY / NASAL | 65 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 13.2 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SOLUTION / ORAL | 40 mg/1ml | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SPRAY / NASAL | 0.01 mg | ||
| eucalyptol | EUCALYPTOL | RV6J6604TK | SOLUTION / NASAL | 0.2 mg/1ml | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 0.22 mg | ||
| eucalyptol | EUCALYPTOL | RV6J6604TK | DROPS / NASAL | 0.2 mg/1ml | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | TABLET / ORAL | 2 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAMUSCULAR | 40 mg | ||
| menthol | MENTHOL | L7T10EIP3A | DROPS / NASAL | 40.32 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 13.2 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SYRUP / ORAL | 70 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / IONTOPHORESIS | 14.2 mg | ||
| camphor (synthetic) | CAMPHOR (SYNTHETIC) | 5TJD82A1ET | JELLY / NASAL | 65 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Afrin Severe Congestion | OXYMETAZOLINE HYDROCHLORIDE | Bayer HealthCare LLC. | a49a506e-aca2-4af0-a50b-dca2c031e61d | 2025-12-05 | Warnings | 11523-7020-1 11523-7020 11523702001 453715d8-b7e1-c347-e063-6294a90a75c8 a49a506e-aca2-4af0-a50b-dca2c031e61d |
Adverse event summaries are temporarily unavailable. Other product information remains available.